Spots Global Cancer Trial Database for acquired resistance
Every month we try and update this database with for acquired resistance cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib | NCT02759835 | Lung Adenocarci... Lung Neoplasms | osimertinib Local Ablative ... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib | NCT02759835 | Lung Adenocarci... Lung Neoplasms | osimertinib Local Ablative ... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
Analysis of Re-biopsy Specimens in Advanced NSCLC With Acquired Resistance of EGFR-TKI Targeted Therapy | NCT03309462 | Lung Cancer | Miseq sequencer | 18 Years - 80 Years | Shanghai Chest Hospital |